LeukemiaPhase 1/2NCT04265963
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1/2 study testing CD123 CAR-T cells in people with Leukemia and Leukemia, Myeloid, run by Chongqing Precision Biotech Co., Ltd at 1 site in China.
Trial summary
There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor. This study purpose to estimate the safety and efficiency of CD123 CAR-T cells to patients with relapse/refractory AML. Read more about this study
- Who is it for?
- Ages 2 to 75 years
- Conditions the study is for
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- What is being tested?
- CD123 CAR-T cells
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2019to 1 Jul 2024
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Signed written informed consent；
- Diagnose as Relapsed/Refractory AML, and meet one of the following conditions：
- With persistent disease after at least two lines of therapy；
- Relapse to the last line of therapy in 6 months，as known as early recurrence;
- Relapse to the last line of therapy after 6 months, but refractory to this last line of therapy；
- Relapse more than once. The definition of relapse: Reappearance of blasts in the blood or bone marrow (>5%) or in any extramedullary site after a CR (the most common are CNS and testicular leukemia).
Show all 19Show fewer
- Evidence for cell membrane CD123 expression;
- KPS>60;
- The expect time of survive is above 3 months;
- Ages: 2 to 75 years;
- All genders;
- The patients that diagnosis as high risks, relapse/refractory or inconformity criteria to other therapy；
- No serious mental disorders;
- Left ventricular ejection fraction ≥40%;
- Sufficient hepatic function defined by ALT/AST<5 x ULN and bilirubin≤34.2μmol/L;
- Sufficient renal function defined by creatinine clearance <220μmol/L;
- Sufficient pulmonary function defined by indoor oxygen saturation≥92%;
- No other illness may conflict with the protocol (e.g. autoimmune diseases, immune deficiency and organ transplantation；
- Ability and willingness to adhere to the study visit schedule and all protocol requirements.
Who cannot join
- Previous history of other malignancy;
- Presence of uncontrolled active infection;
- Evidence of disorder that need the treatment by glucocorticoids;
- Active or chronic GVHD；
- The patients treatment by inhibitor of T cell；
- Pregnant or breasting-feeding women;
- Any situation that investigators regard not suitable for attending in this study (e.g. HIV , HCVinfection or intravenous drug addiction) or may affect the data analysis.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
920th Hospital of Joint Logistics Support Force
Kunming, Yunnan
Sanbin Wang, MD, Sanbin1011@163.com
Sanbin Wang, MD
About this study
There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor. This study purpose to estimate the safety and efficiency of CD123 CAR-T cells to patients with relapse/refractory AML.
Read the detailed description
CD123 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123 cells may prevent relapse of leukemia. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with Acute Myelocytic Leukemia. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Being tested
- CD123 CAR-T cells
- Medical subject headings
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CD123 CAR-T cellsBiological
CD123 CAR-T cell therapy
| Study group | Role | What they receive |
|---|---|---|
| CD123 CAR-T cells treat | Experimental | Patients will be be treated with CD123 CAR-T cells Receives: Biological: CD123 CAR-T cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adverse events that related to treatment
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).
Measured: 2 years
The response rate of CD123 CAR-T treatment in patients with relapse/refractory AML that treatment by CD123 CAR-T cells therapy
The response rate of CD123 CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline.
Measured: 2 years
Secondary outcomes (6)
Cellular kinetics of CD123 CAR-T in Blood
In vivo (peripheral blood) rate and quantity of CD123 CAR-T cells were determined by means of flow cytometry and qPCR
Measured: 2 years
Cellular kinetics of CD123 CAR-T in Bone marrow
In vivo (bone marrow) rate and quantity of CD123 CAR-T cells were determined by means of flow cytometry and qPCR
Measured: 2 years
Cellular kinetics of CD123 positive cells in Bone marrow
In vivo (bone marrow) rate and quantity of CD123 positive cells were determined by means of flow cytometry
Measured: 1 years
Duration of Response (DOR) of CD123 CAR-T treatment in patients with refractory/relapsed AML
DOR will be assessed from the first assessment of CR or CRi to the first assessment of recurrence or progression of the disease or death from any cause (censored)
Measured: 2 years
Progress-free survival(PFS) of CD123 CAR-T treatment in patients with refractory/relapsed AML
PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression (censored)
Measured: 2 years
Overall survival(OS) of CD123 CAR-T treatment in patients with refractory/relapsed AML
OS will be assessed from the first CAR-T cell infusion to death from any cause (censored)
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2020
- Study start1 Sep 2019
- Primary completion31 Dec 2023 (estimated)
- Study completion1 Jul 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chongqing Precision Biotech Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Sanbin Wang, MD, Principal investigator, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaCheng Qian, PhD, Principal investigator, Chongqing University Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04265963
- Sponsor's protocol ID
- PBC011
- Status last verified
- Mar 2023
- First submitted
- 31 Jan 2020
- Last updated
- 18 Apr 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
- ClinicalTrials.gov ID
- NCT04265963
- Acronym / sponsor ID
- PBC011
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Chongqing Precision Biotech Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 1 Sep 2019 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 1 Jul 2024 (estimated)
- First posted
- 12 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor. This study purpose to estimate the safety and efficiency of CD123 CAR-T cells to patients with relapse/refractory AML.
Detailed description
CD123 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123 cells may prevent relapse of leukemia. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with Acute Myelocytic Leukemia. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CD123 CAR-T cells treat | Experimental | Biological: CD123 CAR-T cellsPatients will be be treated with CD123 CAR-T cells |
Who may qualify
- Ages
- 2 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (19 listed)
- Signed written informed consent；
- Diagnose as Relapsed/Refractory AML, and meet one of the following conditions：
- Evidence for cell membrane CD123 expression;
- KPS>60;
- The expect time of survive is above 3 months;
Key exclusion criteria (7 listed)
- Previous history of other malignancy;
- Presence of uncontrolled active infection;
- Evidence of disorder that need the treatment by glucocorticoids;
- Active or chronic GVHD；
- The patients treatment by inhibitor of T cell；
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CD123 CAR-T cellsCD123 CAR-T cell therapy | Biological | CD123 CAR-T cells treat |
Primary outcome
Adverse events that related to treatment
Time frame: 2 years
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).
The response rate of CD123 CAR-T treatment in patients with relapse/refractory AML that treatment by CD123 CAR-T cells therapy
Time frame: 2 years
The response rate of CD123 CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline.
6 secondary outcomes
Cellular kinetics of CD123 CAR-T in Blood
Time frame: 2 years
Cellular kinetics of CD123 CAR-T in Bone marrow
Time frame: 2 years
Cellular kinetics of CD123 positive cells in Bone marrow
Time frame: 1 years
Duration of Response (DOR) of CD123 CAR-T treatment in patients with refractory/relapsed AML
Time frame: 2 years
Progress-free survival(PFS) of CD123 CAR-T treatment in patients with refractory/relapsed AML
Time frame: 2 years
Overall survival(OS) of CD123 CAR-T treatment in patients with refractory/relapsed AML
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2023.
Related trials for Leukemia
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
RecruitingPhase 2/3
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
B-cell Acute Lymphoblastic Leukemia
RecruitingObservational study
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory
RecruitingPhase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
RecruitingPhase 1
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sanbin Wang, MD principal investigator
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Cheng Qian, PhD principal investigator
Chongqing University Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing CD123 CAR-T cells in people with Leukemia and Leukemia, Myeloid, run by Chongqing Precision Biotech Co., Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Zhi Yang, PhD (86-13206140093, yangzhi@precision-biotech.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adverse events that related to treatment (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.